AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors
Abbvie (ABBV) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The Phase 4 study titled “A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor Blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy” compares two approved drugs in adults with moderate plaque psoriasis. It aims to see which option offers better skin clearance and safety in real-world type use, which matters for long-term positioning of AbbVie’s psoriasis franchise.
The trial tests risankizumab, an injectable biologic given under the skin every 12 weeks, against deucravacitinib, a once-daily oral pill. Both aim to reduce red, scaly skin patches by calming the overactive immune response that drives psoriasis and improving patients’ quality of life, but they differ in dosing, route, and likely patient preference.
The study uses a randomized, parallel-group design, meaning participants are assigned to one drug or the other and followed in those groups. It is open-label to patients and treating doctors, but outcome assessors are blinded, so the people rating skin improvement do not know which treatment each person received, and the main goal is to compare treatment benefits and risks.
Participants first receive either risankizumab or deucravacitinib, and then some are re-randomized later to continue or switch treatment, which gives insight into sustained benefit and the effect of switching. The primary aim is treatment, not prevention, and the trial reflects how these medicines might perform in routine care for patients who have not yet used biologic drugs.
The study was first submitted on March 21, 2024, marking the formal launch of the protocol into the public domain. The last update was posted on April 13, 2026, signaling that AbbVie has recently refreshed the record, likely reflecting status changes, follow-up information, or clarifications relevant to investors tracking the psoriasis portfolio.
The trial is listed as completed, which means active treatment and follow-up visits are over, even though formal results are not yet posted. The primary completion and final completion dates are not detailed in the extract, but with completion recorded and a 2026 update, investors can expect data readouts or conference disclosures over the coming quarters.
For AbbVie (ABBV), positive data showing risankizumab outperforming deucravacitinib in moderate plaque psoriasis could reinforce its position as a go-to systemic option, supporting durable revenue in immunology as Humira erosion continues. Strong outcomes could also improve AbbVie’s pricing and formulary leverage within dermatology, stabilizing sentiment around its mid-term growth story.
If the results are mixed or favor deucravacitinib, that could modestly pressure AbbVie’s premium positioning and benefit Bristol Myers Squibb, which owns deucravacitinib, and other oral-focused players in psoriasis. The open-label design, real-world style population, and head-to-head nature mean payers and physicians are likely to view the findings as highly relevant, so the eventual data release may act as a trading catalyst for ABBV and key peers.
The study is now listed as completed and recently updated, with detailed information and future result postings available on the ClinicalTrials portal.
To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.
